The Form 4 filing, a report of changes in an insider's stock ownership, was submitted on Nov. 16, 2026. The trades took place on Nov. 13, 2026. It lists Martine A. Rothblatt as chairperson and chief executive of United Therapeutics (UTHR).
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-13 |
| Date of Latest Transaction | 2026-11-13 |
| Buy/Sell | sell |
| Transaction Count | 12 |
| Shares Transacted | 9,500 |
| Price | $592.42 |
| Total Transaction Value | $5,627,991.42 |
| Insider | |
| Ticker Symbol | UTHR |
| Company | UNITED THERAPEUTICS Corp |
| Insider Name | ROTHBLATT MARTINE A |
| Insider Title | Chairperson & CEO |
| Sector - Industry | Healthcare - Drug Manufacturers - Specialty & Generic |
| Holdings | |
| Total Shares Owned After Transaction | 324,443 |
| Position Size Change | 2.84% |
| Filing | |
| Filing Date | 2026-11-16 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were share sales, reported under transaction code S. The filing lists 12 transactions by one insider.
What was the average price of the transaction?
The average sale price was $592.42 per share across the 12 transactions. Separate prices for each sale were not available.
How did this transaction affect the insider's holdings?
Martine A. Rothblatt sold 9,500 shares and reported owning 324,443 shares afterward. The shares sold made up 2.84% of the reported starting balance of 333,943 shares.
What's the total transaction value?
The 12 sales had a total reported value of $5,627,991.42.
Are there any special circumstances around this transaction?
The transaction information includes a reference to a Rule 10b5-1 trading plan. These plans set trading instructions in advance. The available details do not show whether the reference covers all 12 sales or only some. Footnote text was not available to confirm which trades it covered, when the plan was set up, or its terms.
For research purposes only; not investment advice.